Skip to main content

Month: August 2024

Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow

WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on Thursday, August 29, 2024. Kane Biotech management will host a conference call at 4:30 p.m. ET on August 29, 2024 to review the financial results and discuss business developments in the period. Participants must register for the call using this link: It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A webcast of the call will be available on Kane Biotech’s website at www.kanebiotech.com in the Investor section at ir.kanebiotech.com. About Kane Biotech Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent...

Continue reading

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The Company’s presentation by Sean Brynjelsen, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7am ET. Investors can access the presentation here. To schedule an in-person 1×1 meeting with the Company, please contact Corporate Access at H.C. Wainwright. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial...

Continue reading

Range Announces Retirement of Steve Gray from the Board of Directors

FORT WORTH, Texas, Aug. 22, 2024 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) today announced that Steve Gray will retire from his position on Range’s Board of Directors, effective October 1, 2024. Range Chairman, Greg Maxwell stated, “We want to express our gratitude to Steve for his dedicated service to Range. Since joining our Board in 2018, Steve has shared his wisdom, industry experience and expertise, helping Range to become a more resilient and efficient Marcellus operator capable of generating free cash flow and returns of capital through price cycles. We wish Steve and his family the best in his retirement.” Steve Gray commented, “During my time on the Range Board, I have seen the Company navigate through tough times, volatile commodity prices, and a pandemic, yet emerge as a stronger company. I am proud...

Continue reading

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Posters to be presented highlight clinical study designs investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present two posters in classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. At SSIEM, the Company will present the trial designs of the pivotal Phase 3 HARMONY Study and ENSEMBLE long-term extension study of pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of classical HCU. Additionally, the Company will share the trial design of cohort 7 in the Phase 1/2 COMPOSE Study of pegtibatinase in pediatric participants...

Continue reading

Dillard’s, Inc. Announces $0.25 Cash Dividend

LITTLE ROCK, Ark., Aug. 22, 2024 (GLOBE NEWSWIRE) — Dillard’s, Inc. (DDS-NYSE) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a cash dividend of $0.25 per share on the Class A and Class B Common Stock of the Company. The dividend is payable November 4, 2024 to shareholders of record as of September 30, 2024. CONTACT:Julie J. Guymon, C.P.A. 501-376-5965julie.guymon@dillards.com

Continue reading

CORRECTION — InnovAge PACE Celebrates Anniversary of Vibrant Sacramento Center

PACE Program Provides Highly Coordinated Personalized Senior Care in Partnership with Eskaton and Adventist Health In a release issued under the same headline on Friday, August 16, 2024, by InnovAge, please note the staff count four years ago has been corrected from seven to 20 people. The revised release is as follows: SACRAMENTO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), celebrated the fourth anniversary of its Sacramento, California center with community members, local representatives, businesses, healthcare providers, and other valued partners. “The demand for affordable, reliable healthcare for seniors is...

Continue reading

Toll Brothers Now Selling Move-In-Ready Homes at its Highlands at Vinings Community in Atlanta, Georgia

ATLANTA, Aug. 22, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, is now offering a limited number of quick move-in and move-in ready homes at Highlands at Vinings, a luxury new home community featuring four-story townhomes with private elevators in each residence and sought-after rooftop terraces in Atlanta, Georgia. The community is located at 2741 Wynberry Lane in the vibrant downtown Vinings area of Atlanta. Brand new, move-in ready townhomes in the community are now available starting at $925,000.Highlands at Vinings is a gated community of just 31 luxury townhomes currently offering home designs with up to 3,553 square feet of living space with 3 bedrooms, 4.5 baths, and 2-car garages. The home designs combine sophisticated living with modern architecture and quality...

Continue reading

BC’s Rental Protection Fund Announces Acquisition of 75 Affordable Rental Units in North Vancouver and Squamish

The acquisition will protect two buildings, securing affordable housing for Indigenous people, seniors and families in rapidly growing communities NORTH VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) — Today, the Rental Protection Fund (the Fund) announces the acquisition of two rental buildings; a 35-unit building in North Vancouver acquired by Hiy̓ám̓ ta Sḵwx̱wú7mesh Housing Society (Hiy̓ám̓ Housing) and a 40-unit building in Squamish acquired through a partnership between Hiy̓ám̓ Housing and the Squamish Community Housing Society (Housing Squamish). Both acquisitions will safeguard affordable housing for seniors, families, and Indigenous people in communities where rental housing is in short supply. With capital contributions from the Rental Protection Fund, and a $500,000 investment from the Squamish Nation, Hiy̓ám̓...

Continue reading

MoneyHero Group Announces Non-Binding Offer to Acquire MoneySmart

MoneyHero, the largest and only U.S. publicly traded personal finance platform in Greater Southeast Asia, submits US$8.0 million offer to acquire 100% of the shares of competitor MoneySmart SINGAPORE, Aug. 22, 2024 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a market-leading personal finance and digital insurance aggregation and comparison platform in Greater Southeast Asia, today announced that it has made a non-binding offer to acquire 100% of the shares of MoneySmart, the second largest player in the market. This strategic move aims to consolidate MoneyHero’s leading position and unlock significant synergies in Asia’s rapidly evolving personal finance and insurance landscape. Under the terms of the offer, MoneyHero has valued MoneySmart at US$8.0 million with potential valuation upside....

Continue reading

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA guidance, which stated that KP.2 is the preferred strain for COVID-19 vaccines for the US 2024-2025 fall and winter season, if feasible Shipping will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the countryNEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.